Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä, Finland.
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Dermatology, Tampere University Hospital, Tampere, Finland.
Dig Liver Dis. 2022 Nov;54(11):1502-1507. doi: 10.1016/j.dld.2022.04.016. Epub 2022 May 17.
Celiac disease has been associated with increased mortality, but data on long-term mortality are scarce.
To determine long-term mortality in celiac disease.
The study cohort consisted of all celiac disease patients (n=1,392) diagnosed in Tampere University Hospital catchment area 1960 - 2000. Patients were categorized into subgroups based on demographic (age, gender, decade of diagnosis) and celiac disease characteristics (e.g., phenotype, severity of villous atrophy) collected from medical records. Overall and cause-specific mortality was compared to those of age-, sex-, and place of residence matched reference individuals (n=4,177) over time.
During the 41 years of follow-up (median 26.5 years), 376 celiac disease patients and 1,155 reference individuals died. All-cause mortality was not increased (hazard ratio (HR) 0.96, 95% confidence intervals (CI) 0.85-1.08). Mortality from lymphoproliferative diseases and diseases of the central nervous system was increased (HR 2.42, 95% CI 1.38-4.24 and HR 2.14, 95% CI 1.05-4.36 respectively) while the risk from alcohol related diseases was decreased (HR 0.31, 95% CI 0.09-1.00). Examination of various celiac disease phenotypes revealed no significant differences in mortality CONCLUSIONS: Overall mortality was not increased in any celiac disease phenotype during a very long-term follow-up.
乳糜泻与死亡率增加有关，但有关长期死亡率的数据很少。
确定乳糜泻的长期死亡率。
研究队列包括 1960 年至 2000 年在坦佩雷大学医院集水区诊断的所有乳糜泻患者（n=1392）。根据从病历中收集的人口统计学（年龄、性别、诊断年代）和乳糜泻特征（例如表型、绒毛萎缩严重程度），将患者分为亚组。随着时间的推移，将总体和特定原因死亡率与年龄、性别和居住地匹配的参考个体（n=4177）进行比较。
在 41 年的随访期间（中位数 26.5 年），376 名乳糜泻患者和 1155 名参考个体死亡。全因死亡率没有增加（风险比（HR）0.96，95%置信区间（CI）0.85-1.08）。淋巴增生性疾病和中枢神经系统疾病的死亡率增加（HR 2.42，95%CI 1.38-4.24 和 HR 2.14，95%CI 1.05-4.36），而酒精相关疾病的风险降低（HR 0.31，95%CI 0.09-1.00）。对各种乳糜泻表型的检查表明，在非常长期的随访中，任何乳糜泻表型的死亡率均无显著差异。
在非常长期的随访中，任何乳糜泻表型的总体死亡率均未增加。
